[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper describes EGFR mutations, including L858R, as drivers of tumor growth and drug resistance in non-small cell lung cancer (NSCLC). EGFR functions as a receptor tyrosine kinase, and mutations can lead to constitutive activation of downstream signaling pathways.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly defines EGFR mutations as drivers of tumor growth and constitutive receptor activation, establishing a clear disease mechanism relevant to functional assays.",
        "next_step_or_outcome": "Proceed to Step 2"
      },
      {
        "step_name": "Step 3: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The study utilizes an enzyme activity assay to assess the effect of the L858R mutation on EGFR kinase activity. This assay aims to determine how the mutation impacts the protein's catalytic function.",
        "judgment": "Yes",
        "reasoning": "An enzyme activity assay is appropriate for assessing the direct impact of an EGFR mutation on its kinase function, which is a critical aspect of the defined disease mechanism.",
        "next_step_or_outcome": "Proceed to Step 1.3"
      },
      {
        "step_name": "Step 1.3: Assess Basic Controls & Replicates",
        "extracted_paper_info": "The results section indicates that wild-type EGFR was tested as a control, and the data were compared to a null mutant. Replicates were performed as detailed in the Materials and Methods (n=3).",
        "judgment": "Yes",
        "reasoning": "Both normal/wild-type and abnormal/null controls were used, and the study explicitly states that the experiments were performed in triplicate.",
        "next_step_or_outcome": "Proceed to Step 1.4"
      },
      {
        "step_name": "Step 1.4: Assess Variant Controls",
        "extracted_paper_info": "The study tested other EGFR pathogenic mutations (e.g., T790M) as controls to compare functional changes across mutations.",
        "judgment": "Yes",
        "reasoning": "Pathogenic variants were used as controls to compare the functional changes resulting from different EGFR mutations.",
        "next_step_or_outcome": "Proceed to Step 1.5"
      },
      {
        "step_name": "Step 1.5: Statistical Analyses",
        "extracted_paper_info": "The p-values associated with the differences in kinase activity between the L858R mutant and the wild-type protein were reported. A formal OddsPath calculation was not presented.",
        "judgment": "No",
        "reasoning": "While p-values were provided, a direct OddsPath calculation wasn't included, necessitating the application of broader considerations for strength assignment.",
        "next_step_or_outcome": "Proceed to Step 1.6"
      },
      {
        "step_name": "Step 1.6: Assess Total Benign/Pathogenic Variant Controls",
        "extracted_paper_info": "Based on the description of the studyâ€™s experimental design, at least 11 variant controls were used.",
        "judgment": "Yes",
        "reasoning": "At least 11 pathogenic and benign variants were assessed.",
        "next_step_or_outcome": "Final Interpretation"
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_moderate"
    },
    "overall_conclusion": "The enzyme activity assay demonstrated a significant change in kinase activity for the L858R mutation compared to wild-type EGFR, with a diverse set of variant controls strengthening the finding. However, without a direct OddsPath calculation, the evidence is categorized as PS3_moderate, demonstrating moderate support for the pathogenicity of the L858R mutation."
  }
]